- Preprint Article
- 10.22541/au.175827796.63777628/v1
Prospective Outcomes of PICC Lines in Pediatric Hematology Oncology and BMT: Insights from an LMIC
- Sep 19, 2025
- Sudipto Bhattacharya + 7 more +7
Publications from 2021 to 2026
Showing 10 of 787 papers
Prospective Outcomes of PICC Lines in Pediatric Hematology Oncology and BMT: Insights from an LMIC
Methemoglobinemia Induced by Food During Chemotherapy in a Boy With Acute Lymphoblastic Leukemia and Literature Review.
Methemoglobinemia, a rare and potentially life-threatening condition in pediatric hematology-oncology patients, requires accurate cause identification for effective treatment. We report a case of a 7-year-old boy with acute lymphoblastic leukemia who developed methemoglobinemia during chemotherapy. Initial vitamin C treatment was ineffective, requiring methylene blue. A detailed dietary history revealed the consumption of nitrate-rich vegetables and rapeseed oil, suggesting these as potential triggers. Our literature review highlights the diverse etiologies of methemoglobinemia in this patient population, emphasizing the need for heightened clinical vigilance, and careful differentiation of possible causes to guide appropriate management.
Read moreMild Metabolism Increase on Posttreatment 18 F-FDG PET may Indicate Recurrence of Primary CNS Lymphoma.
In immunocompetent patients, primary central nervous system lymphoma (PCNSL) typically presents with homogeneously enhancing brain lesions and high 18 F-FDG avidity, ranging from 2 to 5 times higher than that of healthy tissue at baseline. We present the case of a 34-year-old woman in whom PCNSL recurrence was questioned due to the appearance of mildly increased glucose metabolism (1.3 times higher than normal contralateral tissue) and FLAIR hypersignals, despite the absence of contrast enhancement or cerebrospinal fluid abnormalities. Histopathology confirmed the recurrence. This case highlights that new 18 F-FDG PET uptake during follow-up, even with lower avidity than baseline, should prompt concern for recurrence or residual disease in PCNSL.
Read moreSilencing of LncRNA XIST Suppressed Tumor Growth andMetastasis in Papillary Thyroid Carcinoma by Modulating miR-204/FN1Axis
Papillary thyroidcarcinoma (PTC) is a prevalent endocrine malignancywith a high incidence rate of regional lymph node metastasis. Dysregulationof lncRNA XIST has been observed in various malignancies. This studyaims to elucidate the molecular mechanism of lncRNA XIST in PTC metastasis.Quantitative real-time PCR assays were conducted to detect the expressionlevels of XIST, FN1, and miR-204–5p in PTC tissues. Meanwhile,loss-of-function assays were employed to evaluate the oncogenic rolesof XIST in PTC cell lines. Our results revealed significant overexpressionof XIST and FN1 in PTC tissues and cell lines, accompanied by decreasedlevels of miR-204–5p (p < 0.05). Knockdownof XIST or FN1 inhibited cellular proliferation, metastasis, and invasionin PTC cells, upregulated E-cadherin, and downregulated N-cadherinand Vimentin. Furthermore, we demonstrated that XIST regulates FN1expression by competitively binding to miR-204–5p. MiRNA inhibitorrescue assays confirmed the pivotal role of the XIST/miR-204/FN1 axisin PTC metastasis and invasion. Our study underscores the oncogenicrole of XIST in PTC by acting as a sponge for miR-204, regulatingFN1 expression. These findings hold promise for advancing our understandingof thyroid cancer and developing potential therapeutic and diagnostictargets for PTC.
Read moreVirus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy.
Human T-lymphotropic virus type 1-associated (HTLV-1-associated) myelopathy (HAM, also known as tropical spastic paraparesis) is a rare neurodegenerative disease with largely elusive molecular mechanisms, impeding targeted therapeutic advancements. This study aimed to identify the critical molecule responsible for neuronal damage in HAM, its source, and the regulatory mechanisms controlling its expression. Utilizing patient-derived cells and established cell lines, we discovered that HTLV-1 Tax, in conjunction with specificity protein 1 (Sp1), enhanced the expression of repulsive guidance molecule A (RGMa), a protein known to contribute to neuronal damage. RGMa expression was specifically upregulated in HTLV-1-infected cells from patients with HAM, particularly in those expressing HTLV-1 Tax. Furthermore, in CD4+ cells from patients with HAM, the level of H3K27me3 methylation upstream of the RGMA gene locus was reduced, making RGMA more prone to constitutive expression. We demonstrated that HTLV-1-infected cells in HAM inflict neuronal damage via RGMa. Crucially, the neutralizing antibody against RGMa, unasnemab (MT-3921), effectively mitigated this damage in a dose-responsive manner, highlighting RGMa's pivotal role in neuronal damage and its potential as a therapeutic target for alleviating neuronal damage in HAM.
Read moreImpact of next-generation sequencing in advanced gastrointestinal cancer.
814 Background: Next-generation sequencing (NGS) is a cutting-edge technology that allows for rapid DNA and RNA sequencing, identifying key mutations in cancer patients. It provides both diagnostic and predictive data for treatment decisions. Approximately 75.6% of US oncologists use NGS testing for patients with advanced solid tumors.This study retrospectively evaluates the impact of NGS testing on treatment outcomes for advanced GI cancer patients at a community-based cancer center in Florida. Methods: Between March 2019 and September 2023, 267 patients with stage 3 or 4 solid malignancies underwent NGS testing. Of these, 77 patients with advanced GI cancer were included in the study. Nearly half (48%) of the patients were diagnosed with advanced-stage colon cancer.NGS testing was performed using tissue samples (79.22%), blood samples (16.88%), or both (3.90%). Demographic and clinical outcomes, including time to diagnosis, treatment initiation, and survival, were collected and analyzed. Results: The median age of the study population was 70, with 88.31% of patients insured through Medicare. The cohort was composed of 61.04% males. Targetable mutations were identified in 59.74% of patients, leading to FDA-approved targeted therapies for 44.16%, and clinical trial eligibility for 79.22%. 52 patients were alive at the time of this analysis; those with biomarkers identified through NGS testing had a median treatment duration of 11 months regardless of whether testing impacted choice of therapy; whereas, patients without identified biomarkers had a median duration of 7.5 months. NGS testing impacted first-line therapy in only 6.49% of all patients; however, 80% of those patients were alive at the time of this analysis with a median duration of response of 5 months. Conclusions: NGS testing has become a cornerstone of oncologic care for advanced solid tumors; however, in this cohort of advanced GI malignancies, NGS results influenced first-line treatment decisions in only 6.49% of cases. Although the study included a small sample size, it reflects a real-world community setting where access to therapies and insurance coverage varies. For example, though patients may have targetable novel therapies available for their disease, the indications for such therapies may not be in the first line setting or covered by insurance. Advancements in NGS targeted therapies has greatly impacted the care of other solid malignancies such as non-small cell lung cancer; however, this study highlights that in the field of GI oncology, there is a large clinically unmet need of identifying newer biomarkers that are clinically relevant and impactful in earlier lines of oncologic care.
Read moreLong-Term Outcomes of Neoadjuvant Intraarterial Chemotherapy for Locally Invasive Lacrimal Gland Carcinoma ex Pleomorphic Adenoma.
There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. The authors reviewed their experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland. Three patients with CXPA of the lacrimal gland treated with neoadjuvant ICAA therapy followed by multimodal therapy at the University of Michigan were retrospectively reviewed. Three patients had stage T4cN0M0 CXPA of the lacrimal gland (American Joint Committee on Cancer 8th ed). The first patient underwent 2 cycles of neoadjuvant IACC followed by multimodal therapy (exenteration, chemoradiotherapy, and adjuvant systemic chemotherapy). At 10 years of follow-up, there was no local recurrence or systemic metastasis. The second patient underwent 1 cycle of neoadjuvant IACC with multimodal therapy (systemic chemotherapy, globe-sparing orbital surgery, and chemoradiotherapy). After 5-year follow-up, there was no local recurrence or systemic metastasis. The third patient underwent 2 cycles of neoadjuvant IACC followed by multimodal therapy (globe-sparing orbital surgery, chemoradiotherapy, and adjuvant systemic chemotherapy). After 2 years, he developed parotid and retromandibular metastasis and underwent total parotidectomy with total neck dissection followed by chemoradiation and systemic anti-androgen therapy. After 7 years, he did not have any local recurrence or systemic metastasis. Neoadjuvant IACC with multimodal therapies can achieve favorable outcomes with locoregional control and improve disease-specific survival in patients with locally invasive advanced-stage CXPA of the lacrimal gland.
Read moreIncreased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps.
Elevated numbers of antibody-secreting cells (ASCs) and anti-double-stranded DNA (anti-dsDNA) antibodies are found in nasal polyp (NP) tissue. The presence of anti-dsDNA IgG in tissue prospectively predicts recurrent NP but the characteristics of the source ASCs are unknown. Here, we investigated whether NP B cells expressing the extrafollicular marker EBI2 have increased propensity for autoantibody production and evaluated the molecular characteristics of NP ASCs. NPs showed increased frequencies of anti-dsDNA IgG and total IgG ASCs compared with tonsils, with more pronounced differences among EBI2+ cells. In NPs, EBI2+ cells were frequently double negative (IgD-CD27-) and ASCs. Single-cell RNA-Seq analysis of tonsils and NPs revealed substantial differences in B lineage composition, including differences in percentages of ASCs, germinal centers, proliferative cells, and non-ASCs. NPs exhibited higher expression of specific isotypes (IGHE, IGHA1, IGHA2, and IGHG4) and mature plasma genes, including SDC1 and XBP1, than tonsils. Gene Ontology biological processes indicated upregulated NF-κB and downregulated apoptosis pathways in NP ASCs. Together, these data indicate that NP EBI2+ ASCs secret increased total and anti-dsDNA IgG compared with those from tonsils and had molecular features of mature plasma cell differentiation.
Read moreHemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
Hemophagocytic lymphohistiocytosis (HLH) has been reported rarely with BRAF/MEK inhibitor combinations, including dabrafenib/trametinib. Postmarketing pharmacovigilance analyses evaluating outcomes associated with dabrafenib/trametinib-induced HLH are also lacking. Herein, we report a case of dabrafenib/trametinib-induced HLH in a patient with metastatic melanoma. Recovery of HLH-related symptoms was observed following drug discontinuation, supportive care, and corticosteroids. We also conducted a pharmacovigilance analysis of the USA Food and Drug Administration Adverse Event Reporting System (FAERS) to describe postmarketing cases of HLH with dabrafenib/trametinib exposure. There were 50 reports of HLH with dabrafenib/trametinib in FAERS. Most cases occurred in the setting of melanoma ( n = 39; 78%) and most were reported in Europe ( n = 39; 74%). Hospitalization was the most common outcome ( n = 39; 78%) of this adverse event per FAERS. HLH is a rare complication of dabrafenib/trametinib, and clinicians should be aware and monitor for signs of this potentially serious and life-threatening adverse event.
Read moreAllogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation